Quinn T Ostrom1,2, Haley Gittleman1,3, Carol Kruchko1, Jill S Barnholtz-Sloan4,5. 1. Central Brain Tumor Registry of the United States, Hinsdale, IL, USA. 2. Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. 3. Department of Population and Quantitative Health Sciences, Case Comprehensive Cancer Center,, Case Western Reserve University School of Medicine, 2-526 Wolstein Research Building, 2103 Cornell Road, Cleveland, OH, 44106-7295, USA. 4. Central Brain Tumor Registry of the United States, Hinsdale, IL, USA. jsb42@case.edu. 5. Department of Population and Quantitative Health Sciences, Case Comprehensive Cancer Center,, Case Western Reserve University School of Medicine, 2-526 Wolstein Research Building, 2103 Cornell Road, Cleveland, OH, 44106-7295, USA. jsb42@case.edu.
Abstract
BACKGROUND: The Appalachian region is a large geographic and economic area, representing 7.69% of the United States (US). This region is more rural, whiter, older, and has a higher level of poverty as compared to the rest of the US. Limited research has been done on primary brain and other central nervous system tumors (PBT) epidemiology in this region. In this analysis we characterize incidence, mortality, and survival patterns. METHODS: Data from 2006 to 2015 were obtained from the central brain tumor registry of the US (provided by CDC and NCI). Appalachian counties were categorized using the Appalachia Regional Council scheme. Overall and histology-specific age-adjusted incidence and mortality rates per 100,000 population were generated. 1-, 5-, and 10-year relative survival (RS) was estimated using CDC national program of cancer registry data from 2001 to 2014. RESULTS: Overall PBT incidence within Appalachia was 22.62 per 100,000, which is not significantly different from the non-Appalachian US (22.77/100,000, p = 0.1189). Malignant incidence was 5% higher in Appalachia (7.55/100,000 vs. 7.23/100,000, p < 0.0001), while non-malignant incidence was 3% lower (15.07/100,000 vs. 15.54/100,000, p < 0.0001). 5-year RS for malignant PBT was lower (31.4% vs. 36.0%), and mortality due to malignant PBT was higher in Appalachia (4.86/100,000 vs. 4.34/100,000, p < 0.0001). CONCLUSION: Appalachia has increased malignant and decreased non-malignant PBT incidence, and poorer survival outcomes for malignant PBT compared to the non-Appalachian US.
BACKGROUND: The Appalachian region is a large geographic and economic area, representing 7.69% of the United States (US). This region is more rural, whiter, older, and has a higher level of poverty as compared to the rest of the US. Limited research has been done on primary brain and other central nervous system tumors (PBT) epidemiology in this region. In this analysis we characterize incidence, mortality, and survival patterns. METHODS: Data from 2006 to 2015 were obtained from the central brain tumor registry of the US (provided by CDC and NCI). Appalachian counties were categorized using the Appalachia Regional Council scheme. Overall and histology-specific age-adjusted incidence and mortality rates per 100,000 population were generated. 1-, 5-, and 10-year relative survival (RS) was estimated using CDC national program of cancer registry data from 2001 to 2014. RESULTS: Overall PBT incidence within Appalachia was 22.62 per 100,000, which is not significantly different from the non-Appalachian US (22.77/100,000, p = 0.1189). Malignant incidence was 5% higher in Appalachia (7.55/100,000 vs. 7.23/100,000, p < 0.0001), while non-malignant incidence was 3% lower (15.07/100,000 vs. 15.54/100,000, p < 0.0001). 5-year RS for malignant PBT was lower (31.4% vs. 36.0%), and mortality due to malignant PBT was higher in Appalachia (4.86/100,000 vs. 4.34/100,000, p < 0.0001). CONCLUSION: Appalachia has increased malignant and decreased non-malignant PBT incidence, and poorer survival outcomes for malignant PBT compared to the non-Appalachian US.
Entities:
Keywords:
Appalachia; Brain and CNS tumors; Incidence; Mortality; Relative survival
Authors: Michael C Veronesi; Mosa Alhamami; Shelby B Miedema; Yeonhee Yun; Miguel Ruiz-Cardozo; Michael W Vannier Journal: Am J Nucl Med Mol Imaging Date: 2020-02-25
Authors: Shilpa Bhatia; Sanjana Bukkapatnam; Benjamin Van Court; Andy Phan; Ayman Oweida; Jacob Gadwa; Adam C Mueller; Miles Piper; Laurel Darragh; Diemmy Nguyen; Ahmed Gilani; Michael Knitz; Thomas Bickett; Adam Green; Sujatha Venkataraman; Rajeev Vibhakar; Diana Cittelly; Sana D Karam Journal: Mol Carcinog Date: 2020-06-22 Impact factor: 4.784
Authors: Hui Xia; Naze G Avci; Yasemin Akay; Yoshua Esquenazi; Lisa H Schmitt; Nitin Tandon; Jay-Jiguang Zhu; Metin Akay Journal: IEEE Open J Eng Med Biol Date: 2020-02-17